News

Prana Surgical lands $12.3M CPRIT grant to validate lung-cancer tool

What's the deal? Prana SurgicalDealroom has a profile for this one. Try Dealroom →, a Houston-based medical technology company, has received a $12,321,572 Product Development Research grant from the Cancer Prevention and Research Institute of Texas (CPRIT)Dealroom has a profile for this one. Try Dealroom →. The money will fund US clinical validation and advancement of the company's FDA-cleared Prana System, a tool for minimally invasive tissue removal.

Why now? This is CPRIT's third award to Prana, following a $3 million grant in 2022 and a $900K supplement in 2025. Those funds backed the system's first clinical procedures in Australia and its US Food and Drug Administration 510(k) clearance in April 2026.

What's the endgame? The Prana System is an image-guided electrosurgical platform that uses CT guidance to locate and excise tissue. One target is lung cancer, the leading cause of cancer death in the US, where wider screening is surfacing more small, hard-to-reach nodules that strain existing techniques.

What's the money for? The grant supports further clinical evaluation and advancement of the system as Prana scales manufacturing, strengthens its supply chain, and expands commercial operations.

Co-founder and chief executive officer Joanna Nathan called it the close to "a banner year for Prana, marked by more major milestones than any other year in our company's history."

The award is one of 76 totaling more than $148 million approved by CPRIT's Oversight Committee, the agency's largest funding action of the year. Prana is among 12 companies selected for product development funding.

The signal: At $12.3 million, the grant ranks in the 95th percentile of all health-sector grant rounds in the US, a sign of growing institutional confidence in surgical tools built for early cancer intervention.

Read more: prweb.com

Image credit: Generated with Gemini

More top stories